[1]杨震,宋景军,杨伟,等.MIR17HG在脑膜瘤中的表达及临床意义[J].中国临床神经外科杂志,2024,29(12):729-733.[doi:10.13798/j.issn.1009-153X.2024.12.006]
　YANG Zhen,SONG Jing-jun,YANG Wei,et al.Expression of MIR17HG in meningioma and its clinical significance[J].,2024,29(12):729-733.[doi:10.13798/j.issn.1009-153X.2024.12.006]
点击复制

MIR17HG在脑膜瘤中的表达及临床意义()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
29
期数:
2024年12期
页码:
729-733
栏目:
论著
出版日期:
2024-12-30

文章信息/Info

Title:
Expression of MIR17HG in meningioma and its clinical significance
文章编号:
1009-153X（2024）12-0729-05
作者:
杨震; 宋景军; 杨伟; 行治国
714000陕西渭南，渭南市中心医院神经外科（杨震、宋景军、杨伟、行治国）
Author(s):
YANG Zhen;  SONG Jing-jun;  YANG Wei;  XING Zhi-guo
Department of Neurosurgery, Weinan Central Hospital, Weinan 714000, China
关键词:
脑膜瘤; miR-17-92基因簇宿主基因（MIR17HG）; 预后
Keywords:
Meningioma;  Host gene of miR-17-92 gene cluster (MIR17HG);  Prognosis
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2024.12.006
文献标志码:
A
摘要:
目的 探讨miR-17-92基因簇宿主基因（MIR17HG）在脑膜瘤中的表达及临床意义。方法 收集2018年11月至2022年3月手术切除的115例脑膜瘤标本，另选择80例因颅脑损伤减压术中切除的非主流脑组织为对照组。采用实时荧光定量PCR法检测MIR17HG水平。脑膜瘤病人术后随访术后随访至2023年11月30日或死亡，记录肿瘤无进展时间和总体生存时间。结果 与对照组相比，脑膜瘤组织MIR17HG水平显著增加（P<0.05）；而且WHO分级Ⅱ、Ⅲ级脑膜瘤组织MIR17HG水平显著高于WHO分级Ⅰ级脑膜瘤（P<0.05）。术后随访0.5~6.0年，中位随访时间3.5年；肿瘤复发/进展28例，死亡14例。多因素Cox回归分析显示，MIR17HG高表达是脑膜瘤病人生存预后不良的独立危险因素（OR=1.734；95% CI 1.304~2.305；P<0.001）。生存曲线分析显示，MIR17HG低表达脑膜瘤无进展生存时间（5.30±0.18年 vs. 3.94±0.31年）和总体生存时间（5.80±0.09年 vs. 4.75±0.27年）明显延长（P<0.05）。结论 脑膜瘤MIR17HG表达水平显著上调，而且其高表达预示着脑膜瘤预后不良。
Abstract:
Objective To explore the expression and clinical significance of the miR-17-92 gene cluster host gene (MIR17HG) in meningiomas. Methods A total of 115 meningioma specimens were collected from November 2018 to March 2022, and 80 non-tumor brain tissues removed during decompressive craniectomy for craniocerebral injury were selected as the control group. The level of MIR17HG was detected by real-time fluorescence quantitative PCR. The patients with meningioma were followed up until November 30, 2023, or death, and progression-free survival (PFS) and overall survival (OS) were recorded. Results Compared with the control group, the level of MIR17HG in meningioma tissues was significantly increased (P<0.05); moreover, the level of MIR17HG in WHO grade Ⅱ and Ⅲ meningioma tissues was significantly higher than that in WHO grade Ⅰ meningioma (P<0.05). The postoperative follow-up period was 0.5 to 6.0 years, with a median follow-up time of 3.5 years; 28 cases of tumor recurrence/progression and 14 deaths were recorded. Multivariate Cox regression analysis revealed that high expression of MIR17HG was an independent risk factor for poor prognosis in patients with meningioma (OR=1.734; 95% CI 1.304~2.305; P<0.001). Survival curve analysis demonstrated that the PFS (5.30±0.18 years vs. 3.94±0.31 years) and the OS (5.80±0.09 years vs. 4.75±0.27 years) of meningiomas with low expression of MIR17HG were significantly prolonged (P<0.05). Conclusion The expression level of MIR17HG in meningiomas is significantly upregulated, and its high expression indicates a poor prognosis for meningiomas.

参考文献/References:

[1] HANNA JRC, WILLMAN M, COLE D, et al. Review of meningioma diagnosis and management [J]. Egypt J Neurosurg, 2023, 38(1): 16-23.
[2] NESLUND O, STRAND PS, SKOGLUND T, et al. Overview and recent advances in incidental meningioma [J]. Expert Rev Anticancer Ther, 2023, 23(4): 397-406.
[3] OGASAWARA C, PHILBRICK BD, ADAMSON DC. Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions [J]. Biomedicines, 2021, 9(3): 319-340.
[4] RANA R, RATHI V, CHAUHAN K, et al. Exploring the role of epidermal growth factor receptor variant III in meningeal tumors [J]. PLoS One, 2021, 16(9): e0255133.
[5] OYA S, IKAWA F, ICHIHARA N, et al. Nation-wide brain tumor registry-based study of intracranial meningioma in Japan: analysis of surgery-related risks [J]. Neurol Med Chir (Tokyo), 2021, 61(2): 98-106.
[6] ZHAO S, GUAN B, MI Y, et al. LncRNA MIR17HG promotes colorectal cancer liver metastasis by mediating a glycolysis-associated positive feedback circuit [J]. Oncogene, 2021, 40(28): 4709-4724.
[7] XU J, HU M, GAO Y, et al. LncRNA MIR17HG suppresses breast cancer proliferation and migration as ceRNA to target FAM135A by sponging miR-454-3p [J]. Mol Biotechnol, 2023, 65(12): 2071-2085.
[8] DENG HS, LIU YB. Overexpression of lncRNA MIR17HG promotes the malignant biological behaviors of cervical cancer HeLa cells and the growth of transplanted tumors in nude mice [J]. Chin J Cancer Biotherapy, 2022, 29(8): 741-749. 邓幻苏，刘元斌. 过表达lncRNA MIR17HG促进宫颈癌HeLa细胞的恶性生物学行为与裸鼠移植瘤生长[J]. 中国肿瘤生物治疗杂志，2022，29（8）：741-749.
[9] MENG Y, HAO D, HUANG Y, et al. Positive feedback loop SP1/ MIR17HG/miR-130a-3p promotes osteosarcoma proliferation and cisplatin resistance [J]. Biochem Biophys Res Commun, 2020, 521 (3): 739-745.
[10] LIU H, ZHU C, XU Z, et al. lncRNA PART1 and MIR17HG as ΔNp63α direct targets regulate tumor progression of cervical squamous cell carcinoma [J]. Cancer Sci, 2020, 111(11): 4129-4141.
[11] CHAO X, FENG X, SHI H, et al. MIR17HG polymorphism (rs7318578) is associated with liver cancer risk in the Chinese Han population [J]. Biosci Rep, 2020, 40(8): BSR20193312.
[12] FENG J, OUYANG Y, XU D, et al. Genetic variants in MIR17HG affect the susceptibility and prognosis of glioma in a Chinese Han population [J]. BMC Cancer, 2020, 20(1): 976-984.
[13] TAN F, CHEN J, DU Z, et al. MIR17HG: a cancerogenic long-noncoding RNA in different cancers [J]. Curr Pharm Des, 2022, 28(15): 1272-1281.
[14] YUAN G, LIU B, HAN W, et al. LncRNA-MIR17HG mediated upregulation of miR-17 and miR-18a promotes colon cancer progression via activating Wnt/β-catenin signaling [J]. Transl Cancer Res, 2019, 8(4): 1097-1108.
[15] YAN J, DENG YX, CAI YL, et al. LncRNA MIR17HG promotes the proliferation, migration, and invasion of retinoblastoma cells by upregulating HIF-1α expression via sponging miR-155-5p [J]. Kaohsiung J Med Sci, 2022, 38(6): 554-564.

相似文献/References:

[1]李春坡　郑　军　李海元　边　涛　韩安国.侧脑室三角区小型脑膜瘤的显微外科治疗[J].中国临床神经外科杂志,2015,(11):694.[doi:10.13798/j.issn.1009-153X.2015.11.018]
[2]王林风　郑华山　操　廉.中央沟区矢状窦旁脑膜瘤的显微手术治疗（附25例报告）[J].中国临床神经外科杂志,2016,(07):431.[doi:10.13798/j.issn.1009-153X.2016.07.014]
[3]邓学云　刘　毅　范润金　刘丽华　夏祥国.E-cadherin与脑膜瘤分级及瘤周水肿的关系[J].中国临床神经外科杂志,2016,(04):213.[doi:10.13798/j.issn.1009-153X.2016.04.007]
　DENG Xue-yun,LIU Yi,FAN Run-jin,et al.Relationship of E-cadherin with the pathological grade of meningioma and peritumoral brain edema in patients with meningioma[J].,2016,(12):213.[doi:10.13798/j.issn.1009-153X.2016.04.007]
[4]马　磊　张海红　郭　康　孙树凯　张　亮　贾　栋.神经导航辅助下手术治疗侧脑室脑膜瘤1例[J].中国临床神经外科杂志,2016,(04):255.[doi:10.13798/j.issn.1009-153X.2016.04.023]
[5]王　一　崔焕喜　林令超　孙思辉　李绍山　周庆九　刘　波　柳　琛.侧脑室三角区脑膜瘤的显微手术治疗[J].中国临床神经外科杂志,2016,(03):161.[doi:10.13798/j.issn.1009-153X.2016.03.010]
　WANG Yi,CUI Huan-xi,LIN Ling-chao,et al.Microsurgery for meningiomas in the trigones of lateral ventricles (report of 47 cases)[J].,2016,(12):161.[doi:10.13798/j.issn.1009-153X.2016.03.010]
[6]王　鹏 综述　王　勇 审校.岩斜区脑膜瘤的手术入路[J].中国临床神经外科杂志,2016,(02):120.[doi:10.13798/j.issn.1009-153X.2016.02.024]
[7]漆松涛　刘　忆.关于WHO2007年版脑膜瘤病理分类一些问题的商榷[J].中国临床神经外科杂志,2016,(02):125.[doi:10.13798/j.issn.1009-153X.2016.02.026]
[8]李登辉　程　荆　李志强.镰旁脑膜瘤术后并发格林巴利综合征1例[J].中国临床神经外科杂志,2016,(02):72.[doi:10.13798/j.issn.1009-153X.2016.02.003]
[9]肖宗宇　陈晓娟　裴　杰　贺瑛福　许常林　马进海.超声吸引器在脑膜瘤手术切除中的应用[J].中国临床神经外科杂志,2015,(10):626.[doi:10.13798/j.issn.1009-153X.2015.10.016]
[10]杨　俊　吴雪松　莫鸿忠　潘荣南　赖　杰.双源CT三维血管成像技术在脑膜瘤术前评估中的应用[J].中国临床神经外科杂志,2015,(06):347.[doi:10.13798/j.issn.1009-153X.2015.06.009]
　YANG Jun,WU Xue-song,MO Hong-zhong,et al.Application of three-dimensional dual-source CT angiography to preoperative assessment of meningiomas[J].,2015,(12):347.[doi:10.13798/j.issn.1009-153X.2015.06.009]

备注/Memo

备注/Memo:
（2024-08-29收稿，2024-09-20修回）
基金项目：陕西省重点研发计划项目（S2021-YF-YBSF-0491）
通信作者：行治国，Email：shxxing526@163.com
更新日期/Last Update: 2024-12-30